These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. A Cure for Sanfilippo Syndrome? A Summary of Current Therapeutic Approaches and their Promise. Pearse Y; Iacovino M Med Res Arch; 2020 Feb; 8(2):. PubMed ID: 32733997 [TBL] [Abstract][Full Text] [Related]
6. Mucopolysaccharidosis type III (Sanfilippo Syndrome): emerging treatment strategies. de Ruijter J; Valstar MJ; Wijburg FA Curr Pharm Biotechnol; 2011 Jun; 12(6):923-30. PubMed ID: 21235449 [TBL] [Abstract][Full Text] [Related]
7. Enzyme replacement therapy and substrate reduction therapy in lysosomal storage disorders with neurological expression. Valayannopoulos V Handb Clin Neurol; 2013; 113():1851-7. PubMed ID: 23622408 [TBL] [Abstract][Full Text] [Related]
8. Substrate-reduction therapy with miglustat for glycosphingolipid storage disorders affecting the brain. Lachmann RH Expert Rev Endocrinol Metab; 2009 May; 4(3):217-224. PubMed ID: 30743792 [TBL] [Abstract][Full Text] [Related]
9. Cell and gene-based therapies for the lysosomal storage diseases. Hodges BL; Cheng SH Curr Gene Ther; 2006 Apr; 6(2):227-41. PubMed ID: 16611044 [TBL] [Abstract][Full Text] [Related]
10. Impact on bone microarchitecture and failure load in a patient with type I Gaucher disease who switched from Imiglucerase to Eliglustat. Sidhu K; Boyd SK; Khan A Mol Genet Metab Rep; 2020 Sep; 24():100606. PubMed ID: 32509532 [TBL] [Abstract][Full Text] [Related]
11. Therapeutic approaches for lysosomal storage diseases: a patent update. Urbanelli L; Sagini K; Polidoro M; Brozzi A; Magini A; Emiliani C Recent Pat CNS Drug Discov; 2013 Aug; 8(2):91-109. PubMed ID: 23713988 [TBL] [Abstract][Full Text] [Related]
12. Current Concepts in the Management of Sanfilippo Syndrome (MPS III): A Narrative Review. Alyazidi AS; Muthaffar OY; Baaishrah LS; Shawli MK; Jambi AT; Aljezani MA; Almaghrabi MA Cureus; 2024 Apr; 16(4):e58023. PubMed ID: 38738088 [TBL] [Abstract][Full Text] [Related]
13. Small-molecule therapeutics for the treatment of glycolipid lysosomal storage disorders. Butters TD; Mellor HR; Narita K; Dwek RA; Platt FM Philos Trans R Soc Lond B Biol Sci; 2003 May; 358(1433):927-45. PubMed ID: 12803927 [TBL] [Abstract][Full Text] [Related]
14. Glyco-engineering strategies for the development of therapeutic enzymes with improved efficacy for the treatment of lysosomal storage diseases. Oh DB BMB Rep; 2015 Aug; 48(8):438-44. PubMed ID: 25999178 [TBL] [Abstract][Full Text] [Related]
15. Recent advances and novel treatments for sphingolipidoses. Arenz C Future Med Chem; 2017 Sep; 9(14):1687-1700. PubMed ID: 28857617 [TBL] [Abstract][Full Text] [Related]
16. How close are we to therapies for Sanfilippo disease? Gaffke L; Pierzynowska K; Piotrowska E; Węgrzyn G Metab Brain Dis; 2018 Feb; 33(1):1-10. PubMed ID: 28921412 [TBL] [Abstract][Full Text] [Related]
17. Biochemistry of glycosphingolipid storage disorders: implications for therapeutic intervention. Aerts JM; Hollak C; Boot R; Groener A Philos Trans R Soc Lond B Biol Sci; 2003 May; 358(1433):905-14. PubMed ID: 12803924 [TBL] [Abstract][Full Text] [Related]